Arana begins Phase II
Thursday, 11 December, 2008
Arana Therapeutics has begun its Phase II trial of its domain antibody ART621 for rheumatoid arthritis.
The trial, which will recruit 200 patients, will held in eight countries, including Australia, the US and India.
It will test the efficacy of ART621 in rheumatoid arthritis and will compare three doses of ART621 with a placebo in patients also taking methotrexate, a common anti-metabolite that inhibits the metabolism of folic acid.
Results are due in mid-2010.
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
Free meningococcal B vaccines coming to the NT
The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
